U.S. markets close in 49 minutes

Jaguar Health, Inc. (JAGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4650-0.0350 (-2.33%)
As of 3:10PM EDT. Market open.

Jaguar Health, Inc.

200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300

Full Time Employees34

Key Executives

NameTitlePayExercisedYear Born
Ms. Lisa A. ConteFounder, CEO, Pres & Director525.21kN/A1959
Mr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & Gen. Counsel336.51kN/A1962
Dr. Steven R. KingChief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.332.23kN/A1958
Ms. Carol R. LizakChief Financial OfficerN/AN/A1964
Dr. Pravin R. Chaturvedi Ph.D.Chair of Scientific Advisory Board & Acting Chief Scientific OfficerN/AN/A1963
Mr. Peter HodgeSr. Director of Investor Relations, Bus. Devel. & Special EventsN/AN/AN/A
Mr. David SesinChief Manufacturing OfficerN/AN/AN/A
Mr. Ian H. Wendt M.B.A.Chief Commercial OfficerN/AN/AN/A
Ms. Melissa A. Yeager J.D.Sr. VP of Regulatory Affairs & Quality AssuranceN/AN/A1954
Dr. Michael K. Guy D.V.M., M.S., Ph.D.VP of Preclinical & Nonclinical StudiesN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

Corporate Governance

Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.